Delivery Order SPE2DB20D1100-SPE2DB25FE5X3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,411.43 under a firm fixed-price contract. The delivery order is non-set-aside and carries an ultimate completion date of September 4, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $16,453.58. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and no set-aside designation was used in the award. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 12, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $4,594.53. This firm fixed-price, competitively awarded delivery order is funded by the Defense Logistics Agency's Medical Supply Chain, a defense-focused federal agency, and has an ultimate completion date of August 13, 2025. The award was made under no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $23,388.90 to AmerisourceBergen Drug Corp for Actemra 162 mg/0.9 mL syringes with a completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child contract under a larger vehicle. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $32,313.93 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed-price contract, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $11,196.02 to AmerisourceBergen Drug Corp for 4,568,895,450 units of Actemra 400 mg/20 mL vials on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract utilizes firm fixed pricing with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a $3,779.36 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-set-aside, firm fixed price contract is scheduled for completion by August 14, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of ACTEMRA 162 mg/0.9 mL syringes with a ceiling value of $4,687.56. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive procurement practices. The order is scheduled for ultimate completion by September 9, 2025, with fulfillment to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,587.35 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, which was competitively awarded without set-aside designation, is scheduled for completion by August 28, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a single transaction under AmerisourceBergen's broader federal contracting relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $7,609.13 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL pharmaceutical product. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of July 30, 2025. The award was made on July 29, 2025, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE5X3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $19,792.71 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed price, competitively awarded contract was executed on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical supply requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies. This delivery order for Actemra, a biologic immunosuppressant medication, reflects the company's ongoing role in supplying specialized pharmaceutical products to support Defense Health Agency and other federal healthcare programs through competitive procurement mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.8k | 9/10/25 |